Award
NIH Reporter #3R34AI198088-01S5
Aggressive antipyretics for neuroprotection and mortality reduction in CNS malaria: A Randomized-Controlled Trial
Recipient
University of Rochester, School of Medicine & Dentistry
Award Amount
$11,873.00
Ceiling
$11,873.00
Awarded
September 14, 2026
Identifier
3R34AI198088-01S5
A phase III clinical trial funded by NIH to test aggressive antipyretic therapy in children with CNS malaria, aiming to reduce mortality and neurodisability.
Description
This project involves a phase III clinical trial to evaluate the efficacy of adjunctive aggressive antipyretic therapy in children with CNS malaria. The study is funded by NIH and conducted by the University of Rochester. The primary outcome measures include mortality, neurodisability, and epilepsy within 3 years post-infection.